Relationship between CDC cross-match in liver recipients and antibody screening by flow cytometry
| Autor: | Luis Marín, Francisco Sánchez-Bueno, M Montes, M.R. Moya-Quiles, M.J Pérez-López, A.M. García-Alonso, Ricardo Robles, Natalia Guerra, Manuel Muro, M.R Álvarez-López, O Montes, Pascual Parrilla, P. Ramirez, A Torı́o, Alfredo Minguela |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Graft Rejection
medicine.medical_treatment T-Lymphocytes Liver transplantation Flow cytometry Allograft survival medicine Humans Autoantibodies Transplantation HLA-D Antigens medicine.diagnostic_test biology business.industry Incidence (epidemiology) Histocompatibility Testing Graft Survival Histocompatibility Antigens Class I Flow Cytometry United States Histocompatibility Liver Transplantation Spain Immunology Acute Disease Chronic Disease biology.protein Surgery Graft survival Antibody Centers for Disease Control and Prevention U.S business Antibody screening |
| Zdroj: | Transplantation proceedings. 35(5) |
| ISSN: | 0041-1345 |
| Popis: | Several authors have shown that anti-donor antibodies before liver transplantation are associated with decreased graft survival. The aim of this study was to investigate the relationship between anti-donor antibodies detected by the CDC technique or by FlowPRA, and acute or chronic rejection as well as graft survival. Furthermore, we sought to determine whether anti-donor antibodies, detected by the CDC technique, correlated with those discovered by cytometric screening. The acute rejection incidence among patients with complement-dependent cytotoxicity positive CDC cross-match was similar to that for patients with a negative cross-match. None of the patients with a positive cross-match developed chronic rejection. Allograft survival was significantly lower among recipients with a positive T-lymphocyte cross-match. Indeed, the majority of recipients with positive CDC cross-matches displayed graft failures before first postransplant year. The results of a positive FlowPRA determination were concordant with a positive CDC cross-match in 85.71% of cases. Our data demonstrate that pretransplant FlowPRA correlates with the final CDC cross-match results. This finding suggests that in the future prospective pretransplant antibody screening with FlowPRA or CDC techniques may be useful to identify high-risk recipients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect